Zacks Investment Research upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a strong-buy rating in a report issued on Tuesday morning, Zacks.com reports. The firm currently has $265.00 price objective on the stock.
According to Zacks, “BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany. “
BNTX has been the subject of several other reports. Bank of America increased their price objective on BioNTech from $341.00 to $349.00 and gave the stock a neutral rating in a research note on Monday, December 6th. SVB Leerink decreased their price target on BioNTech from $293.00 to $268.00 and set a market perform rating for the company in a research report on Tuesday, October 5th. Jefferies Financial Group set a $230.00 price target on BioNTech in a research report on Wednesday, December 8th. TheStreet downgraded BioNTech from a b- rating to a c+ rating in a research report on Wednesday, November 10th. Finally, Deutsche Bank Aktiengesellschaft set a $225.00 price target on BioNTech in a research report on Thursday, December 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of Hold and a consensus price target of $277.93.
BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 8th. The company reported $12.35 EPS for the quarter, topping the consensus estimate of $10.54 by $1.81. The firm had revenue of $6.09 billion during the quarter, compared to the consensus estimate of $5.02 billion. BioNTech had a return on equity of 166.48% and a net margin of 54.34%. The company’s quarterly revenue was up 8918.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.03) earnings per share. On average, equities analysts forecast that BioNTech will post 39.23 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Captrust Financial Advisors boosted its holdings in shares of BioNTech by 4.9% in the third quarter. Captrust Financial Advisors now owns 983 shares of the company’s stock worth $268,000 after acquiring an additional 46 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its stake in BioNTech by 1.3% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,116 shares of the company’s stock valued at $1,124,000 after buying an additional 51 shares during the period. Harbor Investment Advisory LLC boosted its stake in BioNTech by 60.2% during the fourth quarter. Harbor Investment Advisory LLC now owns 149 shares of the company’s stock valued at $38,000 after buying an additional 56 shares during the period. Green Alpha Advisors LLC boosted its stake in BioNTech by 1.9% during the fourth quarter. Green Alpha Advisors LLC now owns 3,570 shares of the company’s stock valued at $920,000 after buying an additional 68 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its stake in BioNTech by 2.2% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,852 shares of the company’s stock valued at $1,052,000 after buying an additional 82 shares during the period. 15.12% of the stock is owned by hedge funds and other institutional investors.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Read More: What is an Initial Coin Offering (ICO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.